T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic malignancy of thymocytes affecting preferentially children and adolescents. The disease is heterogeneous and characterized by a large set of chromosomal and genetic alterations that deregulate the growth of maturing thymocytes. The identification of activating point mutations in NOTCH1 in more then 50% of all T-ALL cases highlights the NOTCH1 cascade as a central player of T-ALL pathogenesis. In this review, we summarize and update more recent findings on the molecular mechanisms of T-ALL with a particular emphasis on the oncogenic properties of aberrant NOTCH1 signaling.
Notch signaling finds its place in T-ALL T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of developing thymocytes. The disease represents 15% of pediatric and 25% of adult acute lymphoblastic leukemia (ALL) cases. It is characterized clinically by high white blood cell counts, increased numbers of blast cells and enlarged mediastinal lymph nodes. Although the disease develops mostly in the thymus, it tends to spread throughout the body, including the central nervous system, complicating the therapeutic treatment of the disease. Historically, T-ALL was associated with a poor outcome; however, today's more aggressive multi-agent chemotherapy results in an overall survival rate of 70% for children and 30-40% for adults below 60 years of age, and 10% above this age [1] . Relapse patients often develop resistance to chemotherapy, and are associated with very poor prognosis. It is therefore important to understand the molecular mechanisms that cause and drive T-ALL to identify novel molecular targets and design more specific therapies.
Over the last two decades, cytogenetic analysis, combined with cloning and sequencing of chromosomal translocation break points, revealed that aberrant expression of numerous transcriptional regulators in T-ALL often involves incorrect rearrangement processes of the T cell receptor (TCR) genes. This results in the juxtaposition of genes coding for transcriptional regulators close to strong TCR gene enhancers and promoters that drive their expression [2] . Examples include a number of basic helixloop-helix (bHLH) transcription factors such as TAL1, TAL2, LYL1, bHLHB1 and MYC, or homeobox transcription factors (Table 1) . Although some of the transcriptional regulators (e.g. MYC) are expressed in normal thymocytes where they govern T cell differentiation and development, others are not of lymphoid origin (e.g. TAL1 or TAL2).
Additional chromosomal translocations, which do not implicate the TCR rearrangement machinery with their strong promoters and enhancers, have also been identified in T-ALL patients. These non-TCR associated translocations lead to the generation of fusion genes and chimeric proteins with novel functions, gene deletions, or gene inactivation as a consequence of promoter hypermethylation, as well as gene duplications (Table 2) .
Although it is in many instances unclear how all of these different genetic defects mechanistically transform thymocytes, this incomplete list shows the large variety of genetic aberrations that contribute to the transformation of T cells. T-ALL does not represent a single disease entity. Gene expression profiling, as well as microarray based competitive genomic hybridization (array-CGH), which detects genomic copy number variations such as deletions and/ or duplications, helped to classify T-ALL patients into multiple subgroups. Some of these subgroups exhibit unique aberrations, whereas others are shared by multiple patient subgroups [3, 4] . More than 50% of T-ALL patients have mutations leading to the hyperactivation of the Notch1 pathway, suggesting that this signaling cascade plays an important role in T-ALL pathogenesis. Box 1 Notch1 is one of four single transmembrane bound Notch receptors, which are composed of an extracellular and an intracellular subunit that are non-covalently linked through the heterodimerization domain (HD) (Figure 1 ). Notch signaling is initiated by receptor-ligand interaction between two neighboring cells, leading to successive proteolytic cleavages, which result in the liberation of the intracellular domain of the receptors (NICD). NICD then translocate to the nucleus and heterodimerizes with the transcription factor CSL/RBPJk to regulate gene expression [5] . This signaling cascade is evolutionarily conserved and regulates many cellular processes, including proliferation, differentiation and survival. Here we summarize recent findings on the differences between human and murine oncogenic Notch1 mutations in T-ALL, and discuss Notch targets and downstream signaling pathways.
Notch1 -key player in T-ALL Notch signaling through the Notch1 receptor has long been shown to be essential for T cell lineage development, thymocyte survival, as well as the proliferation of committed T cell progenitors. Historically, the first evidence of Notch1 being involved in T-ALL was provided when NOTCH1 was identified through the analysis of a chromosomal translocation [t(7;9)(q34;q34.
3)] detected in a small number of T-ALL patients. This revealed that a portion of the human NOTCH1 gene had translocated into the TCRB locus [6, 7] . The oncogenic potential of NOTCH1 was demonstrated in murine bone marrow (BM) reconstitution experiments. Mice reconstituted with BM cells expressing a truncated human form of NOTCH1 developed hematological malignancies characterized as T-ALL [8, 9] . However, the role of NOTCH1 in human T-ALL seemed to be limited because of the rare number of patient cases identified with the t(7;9) translocation (less than 1%; [10] ). A landmark study published in 2004 changed the situation dramatically by showing that more than 50% of T-ALL cases carry Notch1-activating mutations [11] . This finding implicated that Notch1 has a very prominent role in the pathogenesis of T-ALL. Sequence analysis of primary human T-ALL samples and human T-ALL cell lines revealed that the majority of these mutations cluster in 2 general regions either at the PEST or the HD domain of Notch1.
The mutations clustering at the C-terminus of the Notch1 receptor consist of nonsense or frameshift mutations resulting in the deletion of the PEST domain normally regulating NICD degradation [12] . These mutations increase Notch activity through the stabilization of NICD and are present in approximately 20-30% of tumors. The most common NOTCH1 mutations (40-45% of T-ALL patients) fall into exon 26 or 27, which encode the Nand C-terminal HD subunits. Mutations within that region consist of single amino acid changes, short insertions or deletions that maintain the reading frame. These mutations destabilize the interaction between the two subunits, and induce or facilitate ligand-independent Notch1 signaling [13] . Most Notch-dependent human cell lines and approximately 10-20% of primary human T-ALL reveal mutations in both the HD and PEST domains ( Figure 2a ). In retrospect it is not surprising that the frequently occurring mutations in the human NOTCH1 receptor have been associated with human T-ALL given that Notch has been shown to be a potent oncogene in mouse models. Retroviral or transgenic overexpression of NICD in hematopoietic or T cell progenitors is widely used to induce T-ALL in mice [9, 14, 15] . However, sporadic mutations in murine and human T-ALL have only been found so far in Notch1 suggesting that Notch1, and not other Notch receptors, can be a major driver in human T-ALL. Although many T-ALL tumors harbor mutations within the NOTCH1 gene, they contain in addition chromosomal translocations or rearrangements that activate oncogenes or create oncogenic fusion genes (see Tables 1 and 2) . Thus, the question remained whether aberrant Notch signaling is the driver or only a cooperating passenger in human T-ALL.
Although NICD1 is a potent inducer of T-ALL in retroviral and transgenic mouse models, this form of Notch is rarely present in human T-ALL. In mouse models of T-ALL, such as TAL1/SCL, OLIG2 and LMO1/2 transgenic mice (see Table 1 and [16] for review), spontaneous activating Notch1 mutations occur at a high frequency. Therefore, the more commonly mutated Notch1 alleles in the retroviral mouse model have been analyzed. HD, PEST, and HD/PEST mutations more frequently found in human T-ALL samples were weak inducers of Notch activity in vitro, induced only ectopic T cell development, and failed to induce leukemia when tested in the retroviral mouse model [17] . Once these constructs were assayed in an oncogenic background that predisposes to T-ALL, using the LSL-K-ras G12D mouse strain, these weakly leukemogenic alleles shortened disease latency and gave rise to cell
Box 1. Therapeutic targeting of the Notch pathway
The best-documented causative role of activated Notch signaling in human carcinogenesis is certainly T cell acute lymphoblastic leukemia (T-ALL). In recent years aberrant Notch signaling has also been linked to various forms of solid human tumors, and thus, has gained increasing attention as a potential therapeutic target. Initial strategies to block Notch signaling that were also explored in clinical trials, were to use small molecule inhibitors of the g-secretase complex [78] . These chemical compounds block the proteolytic cleavage that liberates the intracellular Notch domain (NICD). However, g-secretase inhibitors are not selective for individual Notch receptors, but they block signaling of all receptors. The most frequently observed side-effect of these compounds is that they cause a dose dependent goblet cell metaplasia in the intestine [79] , since inhibition of Notch1 and Notch2 in intestinal crypt progenitors and/or stem cells induces premature differentiation into goblet cells [80] . However, the gut toxicity can be circumvented when these gsecretase inhibitors are used in combinatorial therapy with glucocorticoids such as dexamethasone [81] . Alternative strategies employing blocking antibodies for specific Notch receptors and/or ligands are being developed currently [81] [82] [83] [84] [85] . The advantage of inhibiting selectively individual Notch receptors or ligands is the minimization of potential side effects. Preclinical cell culture and xeno-transplantation studies indeed indicate that antibody-mediated inhibition of Notch signaling is a promising avenue [83] . Nevertheless, this approach has its limitations. The activity of certain antibodies to block the growth of human T-ALL cell lines bearing Notch1 mutations appears to be less efficient compared to g-secretase inhibitors [86] , possibly owing to lower binding affinity to the mutated receptor. Moreover, tumor cells harboring chromosomal translocations or genetic aberrations, which lead to the expression of Notch receptors lacking their extracellular domain, are not treatable with an antibody-mediated approach. Therefore, alternative approaches must be considered, and were recently pioneered successfully. Stabilized small a-helical peptides derived from the mastermind-like protein were employed to inhibit the Notch transcription complex. These peptides bind to the groove formed by the CSL-NICD complex, and thereby prevent the recruitment of necessary transcriptional coactivators [87] . Treatment of leukemic cells with such peptides inhibited the proliferation of leukemic cells in vitro as well as in a Notch1-driven T-ALL mouse model without causing gut toxicity. Whether any of these or other strategies will be developed successfully into a clinical drug, or will be used in combined drug therapies, remains to be assessed in the future. 
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lines that were Notch-dependent. These data suggest that the common Notch1 mutations found in human T-ALL are likely to be secondary events that contribute to primary oncogenic hits to accelerate tumor progression. However, the tumors arising are still Notch-dependent, because treatment with pharmacological (g-secretase) inhibitors reduced tumor growth. In addition, the growth dependence of T-ALL expressing weak gain-of-function Notch1 alleles, and the strong selective pressure to acquire Notch1 mutations, implied that even weak Notch signals have additional oncogenic roles in development, progression and or maintenance of the disease. Primary among these oncogenic effects are upregulation of Myc (c-Myc) [18] [19] [20] , activation of mTOR [21] , and increased PI(3)-kinase/Akt signaling [22] , all of which have been implicated in the sustained growth of T-ALL cells by Notch1 (Figure 3 ).
Mechanistic differences in oncogenic Notch1 activation in mice and humans Notch receptors comprise a large extracellular domain consisting of EGFR and a negative regulatory region (LNR) that prevents Notch proteolytic cleavage and activation in the absence of ligands (Figure 1) . Thus, it is not surprising that during human T-ALL progression, there is a strong selection for ligand-independent NOTCH1 mutant alleles. The most common NOTCH1 mutations in human T-ALL are clustered within the hydrophobic core of the HD, allowing for ligand-independent cleavage. By contrast, the most common mutations in murine T-ALL are truncations of the PEST domain that enhance the stability of the truncated protein, but mutations in the HD domain are rare [16] . The mutations found in the PEST domain of murine T-ALLs usually arise in leukemogenic backgrounds, such as deficiencies of E2A [23] , p53 [24] , or Ikaros [25] , as well as Tal1 misexpression [24] or constitutive K-ras signaling [17, 26] . Because PEST deletions alone are not oncogenic and most of the murine T-ALLs do not carry mutations in the HD domain, the question how ligand-independent Notch1 activation is initiated in these tumors remained to be clarified. Three recent publications shed new light on this question, and defined deletion-based mechanisms, as well as alternative promoter usage, to support ligand-independent signaling in Notch1 induced T-ALL [27] [28] [29] . Historically, the first clues came from studies characterizing radiation-induced and Atm À/À TALLs, which carried deletion breakpoints at the 5 0 end of the Notch1 gene, and the observation that some tumors generated abnormal, short Notch1 transcripts through illegitimate V(D)J recombination [30] [31] [32] . Therefore, a panel of murine T-ALL cell lines was examined, revealing that most of them harbor deletions within the 5 0 region of the Notch1 gene. These deletions can be divided into two classes: (a) deletions that remove exon 1 and the proximal promoter, and that are RAG-mediated, and (b) deletions that remove sequences between exon 1 and 26 to 28, and that are RAG-independent (Figure 2b) . The RAG-mediated deletions activate an internal promoter that lies within or adjacent to exon 25, and drives the expression of 5 0 deleted Figure 2 . Activating mutations and deletions leading to aberrant Notch1 signaling differ between human and mouse T-ALL (a) A low number of human T-ALL patients carry a t(7;9) translocation, which was mapped to intron 24 and results in the generation of a truncated dominant active Notch1 receptor lacking most of its extracellular domain. Most of the NOTCH1 mutations in humans localize either to the HD domain or to the PEST domain, whereas some T-ALL patients reveal mutations in both domains. In the schematic of NOTCH1, bars and numbers indicate exons and grey boxes indicate reported human mutations. Notch1 transcripts. ChIP-Seq data-mining analysis revealed that RAG2 associates with the 5 0 end of Notch1 in normal thymocytes [28] . Presumably, once RAG2 binds the Notch1 promoter it can recruit RAG1, forming a functional recombinase that mediates illegitimate recombination events because of the presence of ectopic RAG signal sequences. The second type of deletions that remove the region from exon 2 to exon 26-28 occur less frequently, leading to expression of aberrant splice variants from the 5 0 proximal promoter. Although the mechanism for the acquisition of these deletions is not clear, they can arise through random DNA breaks and non-homologous endjoining reactions. Nevertheless, the aberrant transcripts of both classes of deletions initiate translation at a conserved methionine residue (M1727) in the N-terminal region of the transmembrane domain of Notch1 just upstream of the g-secretase cleavage site (Figure 2b ). This results in the generation of a truncated, dominant, active Notch1 protein that is still transported to the cell surface, and therefore requires g-secretase cleavage. This is in line with findings that murine T-ALLs are highly sensitive to g-secretase inhibition [28] .
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Two parallel studies demonstrate that loss of Ikaros also potentiates strongly the transcription of Notch1 alleles harboring 5 0 deletions [27, 29] . Ikaros can bind to the same DNA-binding sequence as RBPJk, and thereby represses Notch target genes [33] . Although inactivating Ikaros mutations are rare in human T-ALL, they occur frequently in mice [34] . Loss-of-function Ikaros mutations cooperate with activating Notch mutations to promote murine T-ALL, suggesting that Ikaros deficiency leads to enhanced Notch target gene expression [25, 35] . Supporting this idea are data generated by conditional inactivation of RBPJk that delayed markedly the onset of T-ALL in Ikaros-deficient mice expressing hypomorphic Ikaros. Thus, T-ALL induced by loss of Ikaros requires canonical Notch signaling. Surprisingly, the onset of T-ALL was enhanced markedly when Ikaros-deficient mice were intercrossed with conditional gene targeted mice for Notch1, in which the 5 0 end of the Notch1 gene was deleted by the expression of a T cell-specific Cre recombinase [27, 29] . This deletion also activates the same cryptic promoter in exon 25 of Notch1 that was responsible for generating aberrant transcripts in tumors with RAG-mediated deletions [28] . These mice expressed high levels of an abnormal short Notch1 transcript encoding a highly active, truncated Notch1 protein, which frequently accumulated mutations within the PEST domain [27] . Epigenetic studies of the Notch1 locus revealed that loss of Ikaros leads to a permissive chromatin configuration and, thus, to the derepression of cryptic promoters present between exon 25 and 27. This results in the generation of aberrant short Notch1 transcripts, which initiate protein translation at the conserved methionine residue M1727 [27, 29] . Therefore, the presence of Ikaros at binding sites within the Notch1 gene locus is required to restrict chromatin accessibility and allows proper gene regulation. Sequence analysis of these cryptic promoter regions within the Notch1 gene revealed the presence of multiple E2A binding sites within or near the Ikaros binding sites. This would suggest that loss of E2A and Ikaros could participate in a common mechanism of transformation generating aberrant Notch1 transcripts in T-ALL that carry deletions of the 5 0 region of the Notch1 gene. Indeed, Notch1 promoter usage in E2A-deficient leukemic cells resulted predominantly in alternative Notch1 transcripts [29] . As a result, these studies indicate that Ikaros, E2A and possibly other proteins restrict chromatin accessibility, thereby suppressing transcriptional initiation from the 3 0 end of Notch1, and thus act as tumor suppressors under physiological conditions.
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Affected signaling pathways by aberrant Notch signaling It has long been known that Notch1 signaling is essential for normal T cell fate specification, as well as thymocyte maturation and progression through and beyond the bselection checkpoint. Thus, it is not surprising that genes and signaling pathways identified downstream of Notch1 in T-ALL cell lines and in vivo mouse models are linked to their physiological role in normal T cell development. The function of aberrant Notch1 signaling in T-ALL can therefore be inferred from its normal purpose. In the context of T cell transformation, signaling through the Notch1 receptor elicits a program of gene expression that supports cell survival and growth, and represses cell cycle arrest and apoptosis. Novel and controversial insights for some of the key players will be discussed below and are highlighted in Figure 2 .
The best-characterized direct target genes include the bHLH transcriptional repressor Hes1 [18, 20, [36] [37] [38] and the transcription factor c-Myc [18] [19] [20] 39] . Important pathways activated through Notch1 signaling include the PI(3)-kinase/Akt [22, 40, 41] and mTOR [21, 42] signaling cascades. Recently, Hes1 was shown to be a key regulator in the induction and maintenance of T-ALL [37, 38, 43] . The use of conditional loss-of-function studies revealed that the transcriptional repressor Hes1 is required for efficient T cell development, and in parallel, Hes1 is also crucial for the development and maintenance of Notch1-induced murine T-ALL [38] . T-ALL cells seem to require persistent Hes1 expression, since Hes1-deficient cells disappear out of the tumor cell population. T-ALL dependence on Hes1 was not only limited to the mouse model, because lentivirusmediated knockdown of Hes1 in human T-ALL cell lines resulted in a severe block in proliferation followed by increased cell death. These studies indicated that Notch1-induced T-ALL are Hes1 dependent, and that Hes1 might have a conserved function in human and mouse T-ALL [38] . Several suggestions for how Hes1 exerts mechanistically its function in T-ALL have been made; nevertheless this issue seems to be unresolved and needs further investigation. Using fly and human T-ALL cell lines, one study implicated Hes 1 in the transcriptional repression of PTEN expression [22] . PTEN is an important tumor suppressor that counteracts the PI(3)-kinase activity, and thereby negatively regulates the Akt/mTOR pathway (Figure 3) . However, in a T-ALL mouse model with conditional Hes1 deficiency, PTEN expression and phospho-Akt levels were unchanged, suggesting that other Notch target genes might be able to compensate for the loss of Hes1 [21] . Thus, the negative effect of Hes1 deficiency on T-ALL development and maintenance must be mediated through other target proteins. Recently, another study implied that Hes1 might repress the deubiquitinase CYLD, which is a negative IKK complex regulator, and thereby sustains NF-kB activation in T-ALL [37, 43] (Figure 3) . CYLD was shown originally to be a tumor suppressor in the skin, and mutations have been identified in familial cylindromatosis [44] . The fact that cylindromatosis patients do not have an increased risk to develop T-ALL, and that CYLD mutations have not been identified in T-ALL patients, indicate that Notch signaling, at least in part, must be able to maintain high NF-kB signaling through alternative pathways.
In normal thymocytes, expression of the proto-oncogene c-myc directly correlates with Notch receptor expression, and thus peaks during b-selection. c-Myc is also a consistently expressed downstream target of NICD in human and mouse T-ALL cell lines (Figure 3) . Inhibition of Notch signaling in these cell lines downregulates rapidly c-Myc, and some T-ALL cell lines can be rescued from loss of Notch signaling by enforced overexpression of c-Myc alone [18] [19] [20] [21] 45] . However, murine T-ALL cell lines that depend upon ectopic c-Myc overexpression can be rescued from Myc withdrawal through NICD1 expression, which induces sufficient levels of endogenous c-Myc [18] . Moreover, a model for a feed-forward loop, through which Notch and c-Myc reinforce the expression of genes required for growth of leukemic cells, has been established recently [20] . These results suggest that Notch-mediated c-Myc expression is crucial for the maintenance of T-ALL. This view was recently challenged by a study employing a tetracycline inducible mouse model for T-ALL, in which c-Myc expression can be turned off in the presence of constitutive NICD or vice versa. In this experimental setting, continuous expression of NICD, but not c-Myc was required for the maintenance of T-ALL, indicating that c-Myc is incapable of maintaining the murine T-ALL tumors in the absence of NICD [46] . These results contrast most of the data obtained with T-ALL cell lines. It is possible that this controversy might be caused by differences in c-Myc expression levels used in both experimental systems. It is conceivable that T-ALL maintenance requires a certain threshold of c-Myc expression, which might have been reached in one but not the other experimental setting.
Although the complex crosstalk between Notch, the signaling pathways and the molecules discussed above, and the additional interactions outlined in Figure 2 are only understood incompletely, it emphasizes the pleiotropic functions of Notch1 signaling. These functions are, to a Review Trends in Immunology September 2011, Vol. 32, No. 9 large extent, reflected as well in its physiological role during T cell development.
Tumor-promoting and suppressive miRNA in Notchinduced T-ALL Micro RNAs (miRNAs), small noncoding RNAs of 19-22 nucleotides, play crucial roles in the translational regulation of protein expression by posttranscriptional silencing. miRNAs are fundamental regulators of physiologically significant cellular processes, and thus, it is not surprising that the deregulation of miRNAs seems to play an important role in human cancers. It has become obvious that miRNAs act as crucial regulators during tumorigenesis, either as oncogenes, as tumor suppressors or even as both, depending on the phase of tumor progression. A role for miRNAs was attributed to affect the normal developmental transitions in T cells through the modulation of TCR signaling strength [44] ; however, the involvement of miRNAs in T-ALL has only been shown recently. A novel translocation targeting the miR-17-19 cluster was reported to coincide with a rearrangement, which in turn activates Notch1 [47] , thereby identifying the interaction between NOTCH1 and miR-19 as a relevant pathogenic mechanism in T-ALL. Coexistence of two translocations activating the NOTCH1 gene (t(9;14)(q34;q11)) and targeting the 17-19 cluster (t(13;14)(q32;q11)) was found in the same leukemic clone. Mechanistically, miR-19 acts on several negative regulators of the PI(3)-kinase pathway, which regulate cell survival in lymphocytes and thus contribute to leukemic progression.
By contrast, miRNAs can also act as tumor suppressors, and recent studies associate tumor suppressive functions during tumor maintenance and metastasis. Examples of miRNAs with tumor suppressing activities include miR15a, miR-16-1 and let7 (reviewed in [43] ). In a very recent publication, two novel miRNAs, miR-451 and miR-709, were identified in NICD1-overexpressing CD4 + CD8 + T cells through miRNA expression profiling [48] . Both miRNAs are transcriptional targets of the bHLH E2A tumor suppressor, which itself is degraded upon NICD1 induction in murine T-ALL cells [39, 45] . The c-Myc oncogene is a target of both miRNAs in mouse T-ALL and human T-ALL cell lines, whereas the miR-709, which has no human homologue, also represses efficiently the oncogenes Akt and Ras-GRF1 in murine T-ALL cells. The concomitant expression of both miRNAs -miR-451 and miR-709 -could block efficiently tumor induction in a retroviral NICDinduced T-ALL mouse model. However, once the NICD1 tumor was established in the mouse, reexpression of miR-451 and miR-709 at physiological levels could only slow tumor progression slightly, because of a counter-selection against cells that expressed increased amounts of two miRNAs. It was suggested that increased Notch activity facilitates the degradation of E2A that would lead to the transcriptional downregulation of miR-451 and miR-709. This, in turn, would lead to the derepression of c-myc and Akt and possibly increased Ras signaling (Figure 3) , and thus promote T-ALL progression. The expression of miR-451 alone in human T-ALL cell lines had no effect on the growth of these cells, and could only inhibit the cell growth in combination with a g-secretase inhibitor (MRK-003).
This implies that miR-451 alone is not able to exert enough tumor suppressive activity, and will most probably work in concert with other regulatory mechanisms to control cell growth and proliferation.
Taken together, the two publications discussed above reveal another facet of control mechanisms in human T-ALL bearing NOTCH1 mutations. However, the mechanistic role of these miRNAs, and possibly others, awaits further clarification.
Concluding remarks
Although T-ALL is a heterogeneous disease in which multiple genetic aberrations cooperate to deregulate proliferation, differentiation and survival of immature thymocytes, more than half of the patients carry activating mutations within the NOTCH1 gene, highlighting its central role in the disease. The oncogenic role of Notch1 is a reflection of its physiological function during normal T cell development. Notch1 is a master regulator for T cell lineage commitment and maturation. However, if Notch1 signaling is not appropriately regulated and shut off at a precise stage during thymocyte development, it exerts oncogenic functions. This will lead to sustained activation of proto-oncogenes and repression of tumor suppressors, in part also by regulating microRNA expression. Recent findings reveal substantial differences in the acquisition of activating Notch1 mutations between murine and human T-ALL. These probably reflect differences in the Notch1 promoter, which favor deletions within the 5 0 region of the Notch1 gene in mouse T-ALL. Despite those differences, Notch1 itself, as well some of its downstream molecules, represent prime targets for developing novel anticancer therapies to fight T-ALL.
